Milliman Healthcare Inflation Plus ETF (MHIP)

On our desk, we are looking closely at MHIP's 0.55% expense ratio alongside its active multi-asset strategy. Because it uses Milliman's Health Trend Guidelines rather than tracking a generic sector index, it provides a specialized hedge against medical cost inflation that traditional equity funds miss entirely.

In our clinic and operational discussions, managing the staggering rise of healthcare expenses remains a top financial threat. MHIP's reliance on proprietary claims data and the world’s preeminent healthcare actuarial firm gives it a distinct analytical edge over standard target-outcome or capital appreciation ETFs.

As a hedge fund PM, I find the launch of MHIP by Milliman particularly timely given how systemic medical cost increases erode retirement savings. Utilizing Milliman Financial Risk Management's risk-managed background gives this product instant credibility among institutional allocators seeking explicit inflation protection.

Watching the fund flow metrics since its April 2026 inception, MHIP is carving out a novel niche in the asset allocation category. By targeting returns that exceed U.S. healthcare cost inflation, it addresses a specific consumer affordability risk that macro fixed income and equities fail to isolate.

From a bio-analyst perspective, connecting portfolio returns directly to the Milliman Health Trend Guidelines bridges a massive gap between clinical cost growth and financial market instruments. It effectively translates complex healthcare industry cost pressures into an investable multi-asset vehicle.